{"id":18439,"date":"2024-02-28T23:30:41","date_gmt":"2024-02-28T23:30:41","guid":{"rendered":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/added-benefit-and-revenues-of-oncology-drugs-approved-by-the-european-medicines-agency-between-1995-and-2020-retrospective-cohort-study\/"},"modified":"2024-03-01T12:33:45","modified_gmt":"2024-03-01T12:33:45","slug":"added-benefit-and-revenues-of-oncology-drugs-approved-by-the-european-medicines-agency-between-1995-and-2020-retrospective-cohort-study","status":"publish","type":"the-bmj-article","link":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/added-benefit-and-revenues-of-oncology-drugs-approved-by-the-european-medicines-agency-between-1995-and-2020-retrospective-cohort-study\/","title":{"rendered":"Added benefit and revenues of oncology drugs approved by the EMA"},"featured_media":0,"template":"","categories":[],"tags":[],"content_type":[36],"editorial_panel":[],"channel_page":[44],"class_list":["post-18439","the-bmj-article","type-the-bmj-article","status-publish","hentry","article-type-research","channel-page-research"],"aioseo_notices":[],"meta_box":{"the_bmj_article-url":"\/content\/384\/bmj-2023-077391","the_bmj_article-description":"A large proportion of oncology drugs approved by the EMA between 1995 and 2020 lack proof of added benefit, finds study","the_bmj_article-the_bmj_article_image":[{"width":150,"height":150,"file":"2024\/02\/european_medicines_agency_ema_PA-57397431.jpg","filesize":240947,"sizes":{"medium":{"file":"european_medicines_agency_ema_PA-57397431-300x194.jpg","width":300,"height":194,"mime-type":"image\/jpeg","filesize":35815,"url":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-content\/uploads\/sites\/4\/2024\/02\/european_medicines_agency_ema_PA-57397431-300x194.jpg"},"thumbnail":{"file":"european_medicines_agency_ema_PA-57397431-150x150.jpg","width":150,"height":150,"mime-type":"image\/jpeg","filesize":22763,"url":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-content\/uploads\/sites\/4\/2024\/02\/european_medicines_agency_ema_PA-57397431-150x150.jpg"}},"image_meta":{"aperture":"2.8","credit":"ABACA\/PA Images","camera":"NIKON D6","caption":"The European Medicines Agency (EMA) comes with its verdict on the Oxford corona vaccine manufacturer AstraZeneca corona vaccine that they have made together. The vaccine is expected to be approved for use in the European Union. The Amsterdam-based EMA gives important advice. The final decision is up to the European Commission. Amsterdam, Netherlands on January 5, 2020. Photo by Robin Utrecht\/ABACAPRESS.COM","created_timestamp":"1609804800","copyright":"ABACA\/PA Images","focal_length":"24","iso":"6400","shutter_speed":"0.004","title":"EMA Approves Oxford\/AstraZeneca Vaccine - Amsterdam","orientation":"1","keywords":["Corona virus Coronavirus Coronavirus 2019-nCoV Coronavirus Covid"]},"ID":"18437","name":"european_medicines_agency_ema_PA-57397431.jpg","path":"\/dom34810\/wp-content\/uploads\/sites\/4\/2024\/02\/european_medicines_agency_ema_PA-57397431.jpg","url":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-content\/uploads\/sites\/4\/2024\/02\/european_medicines_agency_ema_PA-57397431-150x150.jpg","full_url":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-content\/uploads\/sites\/4\/2024\/02\/european_medicines_agency_ema_PA-57397431.jpg","title":"EMA Approves Oxford\/AstraZeneca Vaccine - Amsterdam","caption":"The European Medicines Agency (EMA) comes with its verdict on the Oxford corona vaccine manufacturer AstraZeneca corona vaccine that they have made together. The vaccine is expected to be approved for use in the European Union. The Amsterdam-based EMA gives important advice. The final decision is up to the European Commission. Amsterdam, Netherlands on January 5, 2020. Photo by Robin Utrecht\/ABACAPRESS.COM","description":"","alt":"European Medicines Agency","srcset":false}],"the_bmj_article-related_articles":[{"article_type":"","related_article_title":"","related_article_url":""}],"the_bmj_article-journal_name":""},"head_tags":[{"tag":"title","content":"Added benefit and revenues of oncology drugs approved by the EMA | The BMJ"},{"tag":"meta","attributes":{"name":"robots","content":"max-image-preview:large"}},{"tag":"link","attributes":{"rel":"canonical","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/added-benefit-and-revenues-of-oncology-drugs-approved-by-the-european-medicines-agency-between-1995-and-2020-retrospective-cohort-study\/"}},{"tag":"meta","attributes":{"name":"generator","content":"All in One SEO (AIOSEO) 4.9.6.2"}},{"tag":"meta","attributes":{"property":"og:locale","content":"en_GB"}},{"tag":"meta","attributes":{"property":"og:site_name","content":"The BMJ | The BMJ: leading general medical journal. Research. Education. Comment"}},{"tag":"meta","attributes":{"property":"og:type","content":"article"}},{"tag":"meta","attributes":{"property":"og:title","content":"Added benefit and revenues of oncology drugs approved by the EMA | The BMJ"}},{"tag":"meta","attributes":{"property":"og:url","content":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/added-benefit-and-revenues-of-oncology-drugs-approved-by-the-european-medicines-agency-between-1995-and-2020-retrospective-cohort-study\/"}},{"tag":"meta","attributes":{"property":"article:published_time","content":"2024-02-28T23:30:41+00:00"}},{"tag":"meta","attributes":{"property":"article:modified_time","content":"2024-03-01T12:33:45+00:00"}},{"tag":"meta","attributes":{"name":"twitter:card","content":"summary"}},{"tag":"meta","attributes":{"name":"twitter:title","content":"Added benefit and revenues of oncology drugs approved by the EMA | The BMJ"}},{"tag":"link","attributes":{"rel":"alternate","type":"application\/rss+xml","title":"The BMJ \u00bb Feed","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/feed\/"}},{"tag":"link","attributes":{"rel":"alternate","type":"application\/rss+xml","title":"The BMJ \u00bb Comments Feed","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/comments\/feed\/"}},{"tag":"link","attributes":{"rel":"alternate","title":"oEmbed (JSON)","type":"application\/json+oembed","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/oembed\/1.0\/embed?url=https%3A%2F%2Fbmj-chicken.bmj.com%2Fthebmj%2Fthe-bmj-article%2Fadded-benefit-and-revenues-of-oncology-drugs-approved-by-the-european-medicines-agency-between-1995-and-2020-retrospective-cohort-study%2F"}},{"tag":"link","attributes":{"rel":"alternate","title":"oEmbed (XML)","type":"text\/xml+oembed","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/oembed\/1.0\/embed?url=https%3A%2F%2Fbmj-chicken.bmj.com%2Fthebmj%2Fthe-bmj-article%2Fadded-benefit-and-revenues-of-oncology-drugs-approved-by-the-european-medicines-agency-between-1995-and-2020-retrospective-cohort-study%2F&format=xml"}},{"tag":"link","attributes":{"rel":"https:\/\/api.w.org\/","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/"}},{"tag":"link","attributes":{"rel":"alternate","title":"JSON","type":"application\/json","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/the-bmj-article\/18439"}},{"tag":"link","attributes":{"rel":"EditURI","type":"application\/rsd+xml","title":"RSD","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/xmlrpc.php?rsd"}},{"tag":"meta","attributes":{"name":"generator","content":"WordPress 6.9.4"}},{"tag":"link","attributes":{"rel":"shortlink","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/?p=18439"}},{"tag":"meta","attributes":{"property":"og:locale","content":"en_GB"}},{"tag":"meta","attributes":{"property":"og:site_name","content":"The BMJ"}},{"tag":"meta","attributes":{"property":"og:title","content":"Added benefit and revenues of oncology drugs approved by the EMA"}},{"tag":"meta","attributes":{"property":"og:url","content":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/added-benefit-and-revenues-of-oncology-drugs-approved-by-the-european-medicines-agency-between-1995-and-2020-retrospective-cohort-study\/"}},{"tag":"meta","attributes":{"property":"og:type","content":"article"}},{"tag":"meta","attributes":{"property":"og:description","content":"The BMJ: leading general medical journal. Research. Education. Comment"}},{"tag":"meta","attributes":{"name":"twitter:title","content":"Added benefit and revenues of oncology drugs approved by the EMA"}},{"tag":"meta","attributes":{"name":"twitter:url","content":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/added-benefit-and-revenues-of-oncology-drugs-approved-by-the-european-medicines-agency-between-1995-and-2020-retrospective-cohort-study\/"}},{"tag":"meta","attributes":{"name":"twitter:description","content":"The BMJ: leading general medical journal. Research. Education. Comment"}},{"tag":"meta","attributes":{"name":"twitter:card","content":"summary_large_image"}}],"_links":{"self":[{"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/the-bmj-article\/18439","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/the-bmj-article"}],"about":[{"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/types\/the-bmj-article"}],"type":[{"embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/types\/the-bmj-article"}],"wp:attachment":[{"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/media?parent=18439"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/categories?post=18439"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/tags?post=18439"},{"taxonomy":"article-type","embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/content_type?post=18439"},{"taxonomy":"editorial-panel","embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/editorial_panel?post=18439"},{"taxonomy":"channel-page","embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/channel_page?post=18439"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}